Curi RMB Capital LLC Sells 13,083 Shares of Amgen Inc. $AMGN

Curi RMB Capital LLC cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 31.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,602 shares of the medical research company’s stock after selling 13,083 shares during the period. Curi RMB Capital LLC’s holdings in Amgen were worth $8,911,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Cutter Capital Management LP boosted its position in Amgen by 31.3% in the first quarter. Cutter Capital Management LP now owns 50,000 shares of the medical research company’s stock worth $15,578,000 after purchasing an additional 11,910 shares during the last quarter. Belmont Capital LLC boosted its position in Amgen by 48.8% in the first quarter. Belmont Capital LLC now owns 902 shares of the medical research company’s stock worth $281,000 after purchasing an additional 296 shares during the last quarter. Banque Transatlantique SA boosted its position in Amgen by 8,269.9% in the first quarter. Banque Transatlantique SA now owns 143,292 shares of the medical research company’s stock worth $41,256,000 after purchasing an additional 141,580 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Amgen by 103.0% during the 1st quarter. AQR Capital Management LLC now owns 91,493 shares of the medical research company’s stock valued at $28,321,000 after buying an additional 46,417 shares during the last quarter. Finally, Advisors Asset Management Inc. lifted its position in shares of Amgen by 3.7% during the 1st quarter. Advisors Asset Management Inc. now owns 114,552 shares of the medical research company’s stock valued at $35,689,000 after buying an additional 4,106 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.76% of the stock is owned by corporate insiders.

Amgen Price Performance

Shares of Amgen stock opened at $280.10 on Friday. The firm has a market capitalization of $150.79 billion, a PE ratio of 22.90, a price-to-earnings-growth ratio of 2.47 and a beta of 0.49. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $339.17. The business’s 50-day moving average price is $293.72 and its 200-day moving average price is $292.67. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74. The company had revenue of $9.18 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.Amgen’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the business posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 22nd will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.4%. Amgen’s dividend payout ratio is currently 77.84%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AMGN. UBS Group dropped their price target on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Raymond James Financial started coverage on Amgen in a research note on Wednesday. They set a “market perform” rating on the stock. Cantor Fitzgerald reiterated a “neutral” rating and set a $305.00 price objective on shares of Amgen in a research note on Tuesday, June 24th. Piper Sandler lifted their price target on Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research report on Monday, August 25th. Finally, Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $304.43.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.